Registration Dossier
Registration Dossier
Data platform availability banner - registered substances factsheets
Please be aware that this old REACH registration data factsheet is no longer maintained; it remains frozen as of 19th May 2023.
The new ECHA CHEM database has been released by ECHA, and it now contains all REACH registration data. There are more details on the transition of ECHA's published data to ECHA CHEM here.
Diss Factsheets
Use of this information is subject to copyright laws and may require the permission of the owner of the information, as described in the ECHA Legal Notice.
EC number: 603-923-2 | CAS number: 135590-91-9
- Life Cycle description
- Uses advised against
- Endpoint summary
- Appearance / physical state / colour
- Melting point / freezing point
- Boiling point
- Density
- Particle size distribution (Granulometry)
- Vapour pressure
- Partition coefficient
- Water solubility
- Solubility in organic solvents / fat solubility
- Surface tension
- Flash point
- Auto flammability
- Flammability
- Explosiveness
- Oxidising properties
- Oxidation reduction potential
- Stability in organic solvents and identity of relevant degradation products
- Storage stability and reactivity towards container material
- Stability: thermal, sunlight, metals
- pH
- Dissociation constant
- Viscosity
- Additional physico-chemical information
- Additional physico-chemical properties of nanomaterials
- Nanomaterial agglomeration / aggregation
- Nanomaterial crystalline phase
- Nanomaterial crystallite and grain size
- Nanomaterial aspect ratio / shape
- Nanomaterial specific surface area
- Nanomaterial Zeta potential
- Nanomaterial surface chemistry
- Nanomaterial dustiness
- Nanomaterial porosity
- Nanomaterial pour density
- Nanomaterial photocatalytic activity
- Nanomaterial radical formation potential
- Nanomaterial catalytic activity
- Endpoint summary
- Stability
- Biodegradation
- Bioaccumulation
- Transport and distribution
- Environmental data
- Additional information on environmental fate and behaviour
- Ecotoxicological Summary
- Aquatic toxicity
- Endpoint summary
- Short-term toxicity to fish
- Long-term toxicity to fish
- Short-term toxicity to aquatic invertebrates
- Long-term toxicity to aquatic invertebrates
- Toxicity to aquatic algae and cyanobacteria
- Toxicity to aquatic plants other than algae
- Toxicity to microorganisms
- Endocrine disrupter testing in aquatic vertebrates – in vivo
- Toxicity to other aquatic organisms
- Sediment toxicity
- Terrestrial toxicity
- Biological effects monitoring
- Biotransformation and kinetics
- Additional ecotoxological information
- Toxicological Summary
- Toxicokinetics, metabolism and distribution
- Acute Toxicity
- Irritation / corrosion
- Sensitisation
- Repeated dose toxicity
- Genetic toxicity
- Carcinogenicity
- Toxicity to reproduction
- Specific investigations
- Exposure related observations in humans
- Toxic effects on livestock and pets
- Additional toxicological data
Basic toxicokinetics
Administrative data
- Endpoint:
- basic toxicokinetics
- Type of information:
- experimental study
- Adequacy of study:
- key study
- Reliability:
- 1 (reliable without restriction)
- Rationale for reliability incl. deficiencies:
- guideline study
Data source
Reference
- Reference Type:
- study report
- Title:
- Unnamed
- Year:
- 1 992
- Report date:
- 1992
Materials and methods
- Objective of study:
- excretion
- metabolism
Test guideline
- Qualifier:
- according to guideline
- Guideline:
- EPA OPP 85-1 (Metabolism and Pharmacokinetics)
- Deviations:
- yes
- Remarks:
- limited to animal groups B and D (metabolism following a single oral dosage).
- GLP compliance:
- yes
Test material
- Reference substance name:
- diethyl 1-(2,4-dichlorophenyl)-5-methyl-4,5-dihydro-1H-pyrazole-3,5-dicarboxylate
- EC Number:
- 603-923-2
- Cas Number:
- 135590-91-9
- Molecular formula:
- C16H18Cl2N2O4
- IUPAC Name:
- diethyl 1-(2,4-dichlorophenyl)-5-methyl-4,5-dihydro-1H-pyrazole-3,5-dicarboxylate
Constituent 1
- Radiolabelling:
- yes
- Remarks:
- 14C
Test animals
- Species:
- rat
- Strain:
- Wistar
- Sex:
- male/female
- Details on test animals or test system and environmental conditions:
- TEST ANIMALS
- Source: Hoechst AG, SPF-Zucht Kastengrund
- Age at study initiation: 45-53 days, females: 54-80 days
- Weight at study initiation: males: 205-230 g, females: 190-210 g
- Housing: 2 animals per cage
- Individual metabolism cages: metabolism boxes suitable for separate collection of urine and feces
- Diet (e.g. ad libitum): Altromin 1321 (Altrogge, Lage/Lippe, FRG), ad libitum
- Water (e.g. ad libitum): tap water (municipal water supply), ad libitum
- Acclimation period: about 1 day
ENVIRONMENTAL CONDITIONS
- Temperature (°C): 21-24
- Humidity (%): 18-26
- Photoperiod (hrs dark / hrs light): 12/12
Administration / exposure
- Route of administration:
- oral: gavage
- Vehicle:
- other: sesame oil
- Details on exposure:
- PREPARATION OF DOSING SOLUTIONS:
The preparations containing the radioactively labelled active substance were dissolved in sesame oil. Separate batches of the application mixture were produced for each of the two dose levels
VEHICLE
- Justification for use and choice of vehicle (if other than water): sesame oil, solubility, handling at dosing
- Concentration in vehicle: about 0.2 (1 mg/kg dose group) and 19.9 mg/g formulation (100 mg/kg dose group); specific activities of radiolabelled substance used for preparation of formulation were 1873.7 MBq/g (1 mg/kg dose group) and 33.59 MBq/g (100 mg/kg dose group), respectively.
- Amount of vehicle (if gavage): 0.90-0.94 g solution/animal
HOMOGENEITY AND STABILITY OF TEST MATERIAL:
The solution of radiolabelled test substance in sesame oil was analysed directly and after 24 hours by TLC, UV-VIS and radioactivity determination. The solution was stable during 24 hours at 6°C, a period which was longer than the interval between preparation and the last administration. - Duration and frequency of treatment / exposure:
- single gavage
Doses / concentrationsopen allclose all
- Dose / conc.:
- 1 mg/kg bw/day (nominal)
- Dose / conc.:
- 100 mg/kg bw/day (nominal)
- No. of animals per sex per dose / concentration:
- 5
- Control animals:
- no
- Details on dosing and sampling:
- METABOLITE CHARACTERISATION STUDIES
- Tissues and body fluids sampled (delete / add / specify): urine, faeces, blood (plasma, only high dose group)
- Time and frequency of sampling: urine and faeces over 24 hour-intervals, blood at terminal sacrifice (after 7 d)
- From how many animals: samples from 5 animals per dose pooled
- Method type(s) for identification: HPLC-MS, Liquid scintillation counting
- Limits of detection and quantification: The smallest peak which could be detected unambiguously was about 1 % of the chromatographed radioactivity. If this radioactivity was contained in a 1 % excreta portion, the overall detection limit of this single peak was estimated to be 0.01 % of the dose.
Results and discussion
- Preliminary studies:
- not performed
Toxicokinetic / pharmacokinetic studies
- Details on absorption:
- The renal excretion was the preferred excretion route independent from dose level and sex. As a consequence, the gastro-intestinal absorption rate must at least reach the same level (> 65 - 72%). Longer collection intervals would result in higher levels, as was observed in a parallel pharmacokinetics study. Absorption can thus be assumed to be almost complete.
- Details on excretion:
- The total excretion was fast and already complete within 0-48 hours after oral administration. Thus, 78 - 92% of the dose were excreted within the first 48 hours after dosing. Most of them was excreted with the urine regardless of sex and dose level: 0-24 hours: 58 - 63% of the dose, 24 - 48 hours: 6 - 10% of the dose, 0-48 hours: 65 - 72% of the dose. The faeces of the male animals contained more radioactivity than those of the females regardless of the dose level: 0-48 hours: 24 - 26% of the dose in the males, 13 - 14% of the dose in the females.
In view of the short collection period (0 - 48 hours after dosage), the summed radioactivity in urine and feces resulted in a good balance. Thus the recovered radioactivity amounted to 90 - 92% of the dose in the males and 78 - 86% in the females, regardless of the dose level. Since the main objection of this study was the identification of the residues, excreta of later periods were not investigated. For total balance a pharmacokinetic study was referred to.
High excretion rates were observed within a relatively short interval regardless of dose level and sex. This indicates that the test compound and its metabolites are not retained for long in the animal organism and, consequently, that the enterohepatic circulation would not play a significant role. This conclusion is confirmed by the relatively low portions excreted with the feces.
Metabolite characterisation studies
- Metabolites identified:
- yes
- Details on metabolites:
- HPLC separations of native urine samples showed four different peaks. Peak identification could be performed by thermospray HPLC-MS in the positive mode. This combination showed the [M + H]+ and the [M + NH4]+ions in each case. For additional confirmation of the attributions, the retention times of the HPLC peaks were compared with those of synthesized reference compounds. The following components were observed in the urine: Hoe 113225 [1-(2,4-dichlorophenyl)-5-ethoxycarbonyl-5-methyl-2-pyrazoline-3-carboxylic acid], 109453 [1-(2,4-dichlorophenyl)-5-methyl-2-pyrazoline-3,5-dicarboxylic acid], 094270 [1-(2,4-dichlorophenyl)-5-methyl-pyrazole-3-carboxylic acid]. A difference between the sexes can be evidently observed: The females excreted a significant portion of Hoe 113225 whereas the males increased the proportion of Hoe 109453 in the urine at the same amount. The unchanged parent compound Hoe 107892 could not be detected in the urine.
Whereas the parent Hoe 107892 was the main portion in the feces of the males (0-24 hours: 8% of the dose), the dicarboxylic acid Hoe 109453 predominated in the feces of the females (0-24 hours: 4 - 6%) regardless of the dose level. Hoe 094270 and Hoe 113225 could also be detected in each faeces fraction at lower levels (0.1 - 6% of the dose). The non-extractable portion amounted to 1%, the polar portion which remained in the aqueous phase amounted to 2% of the dose.
Due to a high radioactivity level observed in the plasma during a parallel pharmacokinetic study, plasma samples of the highly dosed rats (male and female) were analysed. In order to reduce the volume carefully and precipitate the proteins, these samples were freezedried and re-dissolved in methanol. HPLC analysis of the methanol solution resulted in a single peak with the same retention at both sexes. The peak obtained from the female rats was identified as Hoe 109453 by HPLC-MS.
Any other information on results incl. tables
Percentage of metabolites in urine:
|
Males |
Females |
||
Metabolite |
0 - 24 h |
24 - 48 h |
0 - 24 h |
24 - 48 h |
Hoe 113225 |
0.2 - 2 |
< 0.1 |
13 - 26 |
0.4 - 1.2 |
Hoe 109453 |
54 - 56 |
6 - 9 |
34 - 43 |
5 - 8 |
Hoe 094270 |
2 - 3 |
0.3 |
2 |
0.2 - 0.3 |
In the urine the dicarboxylic acid Hoe 109453 was the main component in each animal group. The monoester Hoe 113225 was renally excreted in significant portions within the first 24 hours only by the female animals, whereas the Hoe 109453 portion was 2-fold as high as these levels in the urine of the male rats. The pyrazol Hoe 094240 was observed in the 0-24 hours urine of each animal group at the same low level. As expected, the parent compound was not excreted with the urine. Whereas the parent compound Hoe 107892 was the main component in the feces of the male rats, the dicarboxylic acid Hoe 109453 predominated in the feces of the females. Since the fecally excreted radioactivity was higher in males than in females, these findings indicate either a somewhat lower intestinal absorption or a higher biliary excretion of Hoe 107892 in male animals.
Based on the findings in urine and feces the metabolism of Hoe 107892 in the rat is assumed to involve the following steps: the consecutive hydrolysis (saponification) of the two carboxylic acid ester groups and a decarboxylation of one of the carboxylic groups, resulting in an aromatization of the pyrazoline ring. The radioactivity in the blood plasma could be attributed exclusively to the relatively polar dicarboxylic acid Hoe 109453, the main residue component in the urine. No other residue component could be detected.
Applicant's summary and conclusion
Information on Registered Substances comes from registration dossiers which have been assigned a registration number. The assignment of a registration number does however not guarantee that the information in the dossier is correct or that the dossier is compliant with Regulation (EC) No 1907/2006 (the REACH Regulation). This information has not been reviewed or verified by the Agency or any other authority. The content is subject to change without prior notice.
Reproduction or further distribution of this information may be subject to copyright protection. Use of the information without obtaining the permission from the owner(s) of the respective information might violate the rights of the owner.